Insider Selling: Alignment Healthcare (NASDAQ:ALHC) CEO Sells 82,299 Shares of Stock

Key Points

• CEO John Kao sold 82,299 shares on April 13 at an average price of $20.80 under a pre‑arranged Rule 10b5‑1 plan, generating about $1.71 million and reducing his stake by 4.36% to 1,806,641 shares (≈$37.58M).
• ALHC traded around $20.98 (52‑week range $11.63–$23.87) with a $4.29B market cap; the company reported quarterly revenue of $1.01B (up 44.4% YoY) and an EPS of ($0.05) that beat estimates.
• Brokerages collectively rate the stock a consensus "Moderate Buy" with an average target of $24.75 after multiple upgrades, and institutional ownership is high (86.19%) with large firms like Goldman Sachs and RBC materially increasing positions.

Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) CEO John Kao sold 82,299 shares of the company's stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $20.80, for a total value of $1,711,819.20. Following the completion of the sale, the chief executive officer owned 1,806,641 shares in the company, valued at approximately $37,578,132.80. This represents a 4.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Alignment Healthcare Stock Performance

NASDAQ ALHC traded up $0.48 during trading hours on Monday, reaching $20.98. The stock had a trading volume of 1,753,989 shares, compared to its average volume of 3,132,918. The stock has a fifty day moving average of $19.29 and a 200 day moving average of $19.04. The stock has a market cap of $4.29 billion, a P/E ratio of -2,095.90, a price-to-earnings-growth ratio of 3.00 and a beta of 1.20. Alignment Healthcare, Inc. has a 52-week low of $11.63 and a 52-week high of $23.87. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.71 and a current ratio of 1.71.

Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.10. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the company posted ($0.16) earnings per share. Alignment Healthcare's revenue for the quarter was up 44.4% on a year-over-year basis. Sell-side analysts predict that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have issued reports on ALHC. TD Cowen boosted their price target on Alignment Healthcare from $18.50 to $25.00 and gave the company a "buy" rating in a report on Friday, January 16th. Robert W. Baird set a $28.00 price target on Alignment Healthcare in a report on Friday, January 30th. UBS Group boosted their price target on Alignment Healthcare from $18.00 to $21.00 and gave the company a "neutral" rating in a report on Wednesday, January 14th. Piper Sandler boosted their price target on Alignment Healthcare from $20.00 to $30.00 and gave the company an "overweight" rating in a report on Tuesday, January 6th. Finally, KeyCorp reissued an "overweight" rating and issued a $28.00 price target on shares of Alignment Healthcare in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $24.75.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ALHC. Royal Bank of Canada raised its stake in shares of Alignment Healthcare by 92.6% during the 1st quarter. Royal Bank of Canada now owns 92,379 shares of the company's stock worth $1,720,000 after buying an additional 44,413 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Alignment Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company's stock worth $1,109,000 after buying an additional 2,594 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Alignment Healthcare by 79.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company's stock worth $18,112,000 after buying an additional 429,703 shares during the period. Woodline Partners LP acquired a new position in shares of Alignment Healthcare during the 1st quarter worth approximately $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Alignment Healthcare by 16.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company's stock worth $5,729,000 after buying an additional 44,452 shares during the period. 86.19% of the stock is owned by institutional investors and hedge funds.

About Alignment Healthcare

Alignment Healthcare, Inc NASDAQ: ALHC is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare's approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.